Skip to main content

Featured

Market Cools as Nvidia’s Blowout Earnings Fail to Ignite Futures

  U.S. stock futures were mixed Thursday morning as investors digested Nvidia’s latest blockbuster earnings—results that impressed on paper but didn’t translate into broad market enthusiasm. Dow futures edged slightly higher, while S&P 500 and Nasdaq futures hovered near the flatline, reflecting a cautious mood across Wall Street. Nvidia delivered strong beats on quarterly revenue and profit, along with guidance that topped expectations. Despite the stellar numbers, the stock’s initial surge faded as traders questioned whether the AI boom can continue delivering outsized returns. Shares ultimately pared gains to under 1% in early trading. The broader market’s hesitation stems from growing concerns about the sustainability of heavy AI investment. Salesforce’s weaker outlook added to the uncertainty, dragging software shares and reinforcing fears that not all tech giants will benefit equally from the AI wave. Meanwhile, geopolitical tensions—including renewed U.S.–Iran nuclea...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment